Chapter 4.5: People with a cognitive impairment, an intellectual disability, or a mental illness. National Statement on Ethical Conduct in Human Research (2007) - Updated 2018
Introduction – Chapter 4.5
The three kinds of condition discussed in this chapter are different. They are discussed in the one chapter, however, because many of the ethical issues they raise about research participation are very similar.
People with a cognitive impairment, an intellectual disability, or a mental illness are entitled to participate in research. While research involving these people need not be limited to their particular impairment, disability or illness, their distinctive vulnerabilities as research participants should be taken into account.
The capacity of a person with any of these conditions to consent to research, and the ability to participate in it, can vary for many reasons, including:
- the nature of the condition
- the person's medication or treatment
- the person's discomfort or distress
- the complexity of the research project
- fluctuations in the condition.
For example, while intellectual disability is usually permanent, cognitive impairment and mental illness are often temporary or episodic.
Even when capable of giving consent and participating, people with these conditions may be more-than-usually vulnerable to various forms of discomfort and stress.
Research to which this chapter applies must be reviewed and approved by a Human Research Ethics Committee (HREC) rather than by one of the other processes of ethical review described in paragraphs 5.1.7 and 5.1.8, except where that research uses collections of non-identifiable data and involves negligible risk, and may therefore be exempted from ethical review.
Values, principles and themes that must inform the design, ethical review and conduct of all human research are set out in Sections 1 and 2 of this National Statement. The guidelines and headings below show how those values, principles and themes apply specifically in research that is the subject of this chapter.
Guidelines – Chapter 4.5
Research merit and integrity
4.5.1 The research design should take into account factors that may affect the capacity to receive information, to consent to the research, or to participate in it. These factors may be permanent or may vary over time.
4.5.2 Care should be taken to determine whether participants' cognitive impairment, intellectual disability or mental illness increases their susceptibility to some forms of discomfort or distress. Ways of minimising effects of this susceptibility should be described in the research proposal.
4.5.3 People with a cognitive impairment, an intellectual disability, or a mental illness are entitled to participate in research, and to do so for altruistic reasons.
4.5.4 Because of the participants' distinctive vulnerability, care should be taken to ensure that the risks and any burden involved in the proposed research are justified by the potential benefits of the research.
4.5.5 Consent to participation in research by someone with a cognitive impairment, an intellectual disability, or a mental illness should be sought either from that person if he or she has the capacity to consent, or from the person's guardian or any person or organisation authorised by law.
4.5.6 Where the impairment, disability or illness is temporary or episodic, an attempt should be made to seek consent at a time when the condition does not interfere with the person's capacity to give consent.
4.5.7 The process of seeking the person's consent should include discussion of any possibility that his or her capacity to consent or to participate in the research may vary or be lost altogether. The participant's wishes about what should happen in that circumstance should be followed unless changed circumstances mean that acting in accordance with those wishes would be contrary to the participant's best interests.
4.5.8 Consent under paragraph 4.5.6 should be witnessed by a person who has the capacity to understand the merits, risks and procedures of the research, is independent of the research team and, where possible, knows the participant and is familiar with his or her condition.
4.5.9 Where consent has been given by a person authorised by law, the researcher should nevertheless explain to the participant, as far as possible, what the research is about and what participation involves. Should the participant at any time recover the capacity to consent, the researcher should offer him or her the opportunity to continue participation (under the terms of paragraph 4.5.6) or to withdraw.
4.5.10 Researchers should inform HRECs how they propose to determine the capacity of a person with a cognitive impairment, an intellectual disability, or a mental illness to consent to the research. This information should include:
- (a) how the decision about the person's capacity will be made
- (b) who will make that decision
- (c) the criteria that will be used in making the decision
- (d) the process for reviewing, during the research, the participant's capacity to consent and to participate in the research.
4.5.11 Refusal or reluctance to participate in a research project by a person with a cognitive impairment, an intellectual disability, or a mental illness should be respected.
Authors of this National Statement
This National Statement has been jointly developed by the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC) and Universities Australia (UA). This joint undertaking reflects a widely shared conviction that there is a need for ethical guidelines that are genuinely applicable to all human research and it gives expression to the shared responsibility for ethically good research described above.
Clinical Research News
- Jan 16
- Jan 11
- Jan 10
- Dec 16
- Dec 13
- Dec 06
- Dec 06
- Dec 05
- Dec 05
- Nov 23
Upcoming Clinical Trials
NCT05705544Not yet recruitingPeripheral Pulmonary Lesions
NCT05705531Not yet recruitingAssessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma SurvivorsCardiovascular Diseases Hodgkin Lymphoma Clonal Hematopoiesis of Indeterminate Potential Therapy-related Clonal Hematopoiesis
NCT05705518Not yet recruiting
NCT05705492Not yet recruitingOlanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced and Incurable Solid TumorsAdvanced Malignant Solid Neoplasm
NCT05705505Not yet recruitingStudy of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial CancerEndometrioid Endometrial Cancer
NCT05705401Not yet recruiting
NCT05705440Not yet recruiting
NCT05705323Not yet recruitingSleep Tinnitus Depression, Anxiety Distress, Emotional
Clinical Research Jobs
Clinical Trial Oversight Lead
Senior Associate, Pricing and Market Access EMEA
Research Associate Enrollment (Entry Level)
Facilities Project Lead - Physical Plant
Molecular Technologist - Sequencing I
Research Scientist- DSE
Customer Service Manager 1
Manufacturing Science Associate I (EG)
Breeder Technician II
Research Associate I - In Vivo DMPK